|
Maternal serum screening, or the quad screen, is performed on peripheral blood samples typically collected between 15 and 18 weeks of pregnancy. The quad screen measures levels of alpha-fetoprotein (AFP), human chorionic gonadotropin (beta-HCG), unconjugated estriol (uE3), and Inhibin-A in the mother's blood to determine the fetus' risk of a birth defect. Potential defects include Down syndrome or trisomy 21, neural tube defect, and other chromosome abnormalities. Screening also detects increased risk of multiple gestation, molar pregnancy or fetal demise.
Alpha-fetoprotein Testing
Alpha-fetoprotein (AFP) is produced by the fetal liver and is normally detected in the amniotic fluid (AF). Significant elevations in AF-AFP levels are associated with the presence of neural tube defects, abdominal wall defects or congenital nephrosis. Reflex testing for the enzyme acetylcholinesterase (AChE) is indicated when AF-AFP is significantly elevated.
 Test Information and Specimen Requirements
For more information about the maternal serum screening, contact one of our service specialists at 800-932-2943.
Our Testing Resources
 Prenatal testing services available
 Prenatal screening brochure for patients
Prenatal diagnosis brochure for patients
|
